(Q37559275)

21 August 2017

1 reference

title

Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia (English)

1 reference

21 August 2017

0 references

1 reference

A Osterborg

1 reference

21 August 2017

R Foà

1 reference

21 August 2017

R F Bezares

1 reference

21 August 2017

C Dearden

1 reference

21 August 2017

M J S Dyer

1 reference

21 August 2017

C Geisler

1 reference

21 August 2017

T S Lin

1 reference

21 August 2017

M Montillo

1 reference

21 August 2017

M H J van Oers

1 reference

21 August 2017

C-M Wendtner

1 reference

21 August 2017

K R Rai

1 reference

21 August 2017

publication date

23 July 2009

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

21 August 2017

page(s)

1980-1988

1 reference

21 August 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Disease burden of chronic lymphocytic leukaemia within the European Union

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Regulatory T cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Strategies in the management of alemtuzumab-related side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

7 January 2021

Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

7 January 2021

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

7 January 2021

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

7 January 2021

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

7 January 2021

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

7 January 2021

Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

7 January 2021

Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

7 January 2021

Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.146

7 January 2021

Identifiers

DOI

10.1038/LEU.2009.146

1 reference

21 August 2017

1 reference